drugset / Trial / NCT00525044

Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat

NCT00525044

Phase 3 Completed 249 enrolled Boehringer Ingelheim
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this trial is to investigate the efficacy and tolerance of Ambroxol lozenges 20 mg in the treatment of sore throat in patients with acute viral pharyngitis.

Timeline

Start
2007-08-01
Primary completion
2008-01-01
Completion
2008-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambroxol Small molecule 20 mg

Indications